Viasystems Group, Inc. (NASDAQ:VIAS) expects to release results for the quarter ended June 30, 2012 on Wednesday, August 8, 2012.
Management plans to discuss the results of the quarter during a conference call with investors at 11:00 a.m. Eastern Time on August 8, which Viasystems will broadcast live via the Internet.
**************
Video marketing on the internet has become a sensational method of advertising various items and services. Intelligent business owners from small, medium, to large company have been very active on the activity of recording online videos and posting them to social media or to their own web sites merely because they are powerful.
Crown Equity Holdings Inc., (CRWE) recenly launched CRWE Tube, www.crwetube.com, a video sharing site that allows billions of people around the world to upload, watch and share original videos.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWEs advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
More about CRWE at www.crownequityholdings.com
**************
Nautilus, Inc. (NYSE:NLS) will report its financial results for the second quarter ended June 30, 2012 after the market closes on Monday, August 6, 2012, followed by a management hosted conference call to discuss the Companys operating results.
**************
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) reported the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).
The EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-naïve CML patients. The efficacy of ponatinib will be assessed in comparison to imatinib based on evaluation of the primary endpoint of major molecular response (MMR) rate at 12 months. ARIAD expects to complete patient enrollment in the trial by the end of 2013.
***********************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreetNewsAlert.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://crwewallstreetnewsalert.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreetNewsAlert.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.
Add new comment